June 4, 2024 07:30 AM EDTUpdated 07:41 AM

BridgeBio spotlights 12 and 18-month data for potential achondroplasia drug in children

Katherine Lewin

News Reporter

BridgeBio touted longer-term data for its achondroplasia drug infigratinib from a mid-stage trial on Tuesday, setting the treatment up to be a future competitor for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio spotlights 12 and 18-month data for potential achondroplasia drug in children

Katherine Lewin

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Bridge­Bio spot­lights 12 and 18-month da­ta for po­ten­tial achon­dropla­sia drug in chil­dren

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

BridgeBio spotlights 12 and 18-month data for potential achondroplasia drug in children